SKF 81297 | 743408-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: SKF 81297
• 英文别名: 6-CI-PB；(1R)-6-Chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol；(5R)-9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
• CAS: 743408-71-1
• 化学式: C₁₆H₁₆ClNO₂
• 分子量: 289.762
• InChiKey: GHWJEDJMOVUXEC-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  碘甲烷-13C 、 SKF 81297 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺-d7 为溶剂， 生成 (5R)-9-chloro-7-(113C)methoxy-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-8-ol 、 、 R-[N-methyl-13C]SKF 82957
  参考文献：
  名称：

  Gillies; Luthra; Brady, Journal of labelled compounds and radiopharmaceuticals, 1999, vol. 42, # SUPPL. 1, p. S462-S464

  摘要：

  DOI：

文献信息

• Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
  申请人：PFIZER INC.

  公开号：US20150291625A1

  公开（公告）日：2015-10-15

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β-arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

  本发明部分提供了公式I的化合物：及其药学上可接受的盐和N-氧化物；其制备的过程和中间体；以及其组合物和用途。本发明进一步提供具有减少D1R脱敏作用的D1激动剂，具有相对于多巴胺减少β-阻滞素招募活性的D1激动剂，当结合到D1R时与Ser188显著相互作用但与Ser202显著相互作用较少的D1激动剂，与D1R结合时与Asp103相互作用较弱且与Ser198相互作用较弱的D1激动剂及其用途。
• HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
  申请人：Pfizer Inc.

  公开号：EP2917219B1

  公开（公告）日：2017-09-27
• ACTIVATION OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL
  申请人：Tsai Li-Huei

  公开号：US20100075926A1

  公开（公告）日：2010-03-25

  The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.
• US9617275B2
  申请人：——

  公开号：US9617275B2

  公开（公告）日：2017-04-11
• [EN] ACTIVATIQN OF HISTONE DEACETYLASE 1 (HDAC1) PROTECTS AGAINST DNA DAMAGE AND INCREASES NEURONAL SURVIVAL<br/>[FR] L'ACTIVATION DE L'HISTONE DÉSACÉTYLASE 1 (HDAC1) PROTÈGE CONTRE DES LÉSIONS DE L'ADN ET AUGMENTE LA SURVIE NEURONALE
  申请人：MASSACHUSETTS INST TECHNOLOGY

  公开号：WO2010011318A2

  公开（公告）日：2010-01-28

  The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDACl activators. Exemplary HDACl activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+-)-4-amino-3-(5- chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.